The Ki-67/MIB-1 index level and recurrence of papillary thyroid carcinoma

Medical Hypotheses

Volumn 80, Issue 3, 2013, Pages 311-314

  Ranjbari, Nastaran ^a   Rahim, Fakher ^b  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; THYROID CARCINOMA;

CARCINOMA, PAPILLARY; HUMANS; KI-67 ANTIGEN; MODELS, THEORETICAL; THYROID NEOPLASMS;

EID: 84874512355     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.12.015     Document Type: Article

References (63)

1. Choi Y.J., Park Y.L., Koh J.H. Prevalence of thyroid cancer at a medical screening center: pathological features of screen-detected thyroid carcinomas. Yonsei Med J 2008, 49(5):748-756.
2. Seehofer D., et al. Prevalence of thyroid nodules and carcinomas in patients operated on for renal hyperparathyroidism: experience with 339 consecutive patients and review of the literature. World J Surg 2005, 29(9):1180-1184.
3. Verdi D., et al. Synchronous medullary, papillary and follicular carcinomas in the same thyroid: case report and review of literature. Updates Surg 2012.
4. Todd W.U.T., Wenig B.M. Thyroid follicular epithelial cell-derived carcinomas: an overview of the pathology of primary and recurrent disease. Otolaryngol Clin North Am 2008, 41(6):1079-1094. [vii-viii].
5. Goldstraw P., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2(8):706-714.
6. Groome P.A., et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2(8):694-705.
7. Wohlschlager J., Wittekind C., Theegarten D. New TNM classification of malignant lung tumours. Pathologe 2010, 31(5):355-360.
8. Boucek J., et al. Occult thyroid carcinoma. Acta Otorhinolaryngol Ital 2009, 29(6):296-304.
9. Ito Y., et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 2005, 68(2-3):87-96.
10. Gerdes J., et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991, 138(4):867-873.
11. van Dierendonck J.H., et al. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res 1989, 49(11):2999-3006.
12. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23(28):7212-7220.
13. Wallin G., et al. Nuclear protein content and Ki-67 immunoreactivity in nonneoplastic and neoplastic thyroid cells. Anal Quant Cytol Histol 1992, 14(4):296-303.
14. Basolo F., et al. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 1997, 75(4):537-541.
15. Ito Y., Miyauchi A. Prognostic factors of papillary and follicular carcinomas in Japan based on data of kuma hospital. J Thyroid Res 2012, 2012:973497.
16. Ito Y., et al. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg 2010, 34(12):3015-3021.
17. Nakayama H., et al. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 2007, 27(5B):3645-3649.
18. Kjellman P., et al. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 2003, 13(4):371-380.
19. Pelizzo M.R., et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 2006, 32(10):1144-1148.
20. Roti E., et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006, 91(6):2171-2178.
21. Wada N., et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003, 237(3):399-407.
22. Chow S.M., et al. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003, 98(1):31-40.
23. Ito Y., Miyauchi A. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat Clin Pract Endocrinol Metab 2007, 3(3):240-248.
24. Mian C., et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 2011, 164(6):971-976.
25. Souza G.D., et al. Citophotometric expression of the factor of cellular proliferation ki-67 in the goiter colloid and in the papillary carcinoma of the thyroid. Rev Col Bras Cir 2009, 36(2):105-109.
26. Lee Y.S., et al. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma. Exp Mol Pathol 2010, 88(1):138-142.
27. Manaios L., et al. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis. J BUON 2008, 13(4):537-541.
28. Lim D.J., et al. Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 2007, 17(9):883-888.
29. Lantsov D., et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 2005, 47(3):248-256.
30. Semba S., et al. Nuclear accumulation of B-catenin in human endocrine tumors: association with Ki-67 (MIB-1) proliferative activity. Endocr Pathol 2000, 11(3):243-250.
31. Yano S., et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000, 58(5):1980-1986.
32. Kleer C.G., Giordano T.J., Merino M.J. Squamous cell carcinoma of the thyroid: an aggressive tumor associated with tall cell variant of papillary thyroid carcinoma. Mod Pathol 2000, 13(7):742-746.
33. Tallini G., et al. Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 1999, 23(6):678-685.
34. Pujani M., et al. Role of Ki-67 as a proliferative marker in lesions of thyroid. Indian J Cancer 2010, 47(3):304-307.
35. Konturek A., et al. Prognostic factors in differentiated thyroid cancer-a 20-year surgical outcome study. Langenbecks Arch Surg 2012, 397(5):809-815.
36. Mussig K., et al. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. Clin Endocrinol (Oxf) 2012, 77(1):139-145.
37. Erickson L.A., et al. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998, 11(2):169-174.
38. de Azambuja E., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96(10):1504-1513.
39. Whitfield M.L., et al. Common markers of proliferation. Nat Rev Cancer 2006, 6(2):99-106.
40. Cattoretti G., et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168(4):357-363.
41. Cui W., et al. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Clin Lab 2012, 58(5-6):419-426.
42. Sofiadis A., et al. Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol 2009, 35(2):369-374.
43. Rickert D., et al. MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland. Anal Quant Cytol Histol 2000, 22(3):229-234.
44. Aiad H.A. Significance of AgNORs and Ki-67 proliferative markers in differential diagnosis of thyroid lesions. Pathol Oncol Res 2012.
45. Dhall D., et al. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol 2012, 43(4):489-495.
46. Ozaki O., et al. Anaplastic transformation of papillary thyroid carcinoma in recurrent disease in regional lymph nodes: a histologic and immunohistochemical study. J Surg Oncol 1999, 70(1):45-48.
47. Sittel C., et al. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol 1999, 35(6):583-589.
48. Ranganathan K., Kavitha R. Proliferation and apoptosis markers in oral submucous fibrosis. J Oral Maxillofac Pathol 2011, 15(2):148-153.
49. Garzetti G.G., et al. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol Oncol 1995, 58(1):28-33.
50. Van de Putte G., et al. Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol 2004, 92(1):40-46.
51. Dinets A., et al. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. Eur J Endocrinol 2012, 166(6):1049-1060.
52. Kazakov S.P., et al. Comparative analysis of cells with combined apoptosis and proliferation markers in thyroid tissue specimens from patients with cancer, adenoma, and autoimmune diseases. Bull Exp Biol Med 2011, 150(4):453-458.
53. Choudhury M., Singh S., Agarwal S. Diagnostic utility of Ki67 and p53 immunostaining on solitary thyroid nodule - a cytohistological and radionuclide scintigraphic study. Indian J Pathol Microbiol 2011, 54(3):472-475.
54. Weigel M.T., Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 2010, 17(4):R245-62.
55. Cheang M.C., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
56. Siironen P., et al. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 2005, 26(2):57-64.
57. Ludvikova M., et al. Role of the MIB-1 proliferative markers in the diagnosis and prognosis of tumors of the thyroid gland. Cesk Patol 2002, 38(1):4-10.
58. Ludvikova M., et al. Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining. Anticancer Res 2005, 25(3A):1835-1840.
59. Bevilacqua P., et al. Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat 1996, 37(2):123-133.
60. Bos R., et al. Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97(6):1573-1581.
61. Keshgegian A.A., Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 1995, 104(1):42-49.
62. Liu S., et al. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 2001, 7(6):1716-1723.
63. Spyratos F., et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002, 94(8):2151-2159.